RIZE — Rize Oncology Income Statement
0.000.00%
Last trade - 00:00- CA$2.27m
- CA$0.68m
- 25
- 30
- 19
- 13
Annual income statement for Rize Oncology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 0.072 | 1.64 | 1.72 | 0.747 | 0.589 |
| Operating Profit | -0.072 | -1.64 | -1.72 | -0.747 | -0.589 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -0.073 | -1.64 | -1.72 | -0.688 | -0.551 |
| Net Income After Taxes | -0.073 | -1.64 | -1.72 | -0.688 | -0.551 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.073 | -1.64 | -1.72 | -0.688 | -0.551 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -0.073 | -1.64 | -1.72 | -0.688 | -0.551 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.001 | -0.033 | -0.04 | -0.015 | -0.014 |
| Dividends per Share |